Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016;5(3):288–300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang SR, Schultheis AM, Yu H, Mandelker D, Ladanyi M, Buttner R. Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol. 2022;84:184–98.

Article  CAS  PubMed  Google Scholar 

Li WQ, Cui JW. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments. J Cancer Res Clin Oncol. 2020;146(9):2329–38.

Article  CAS  PubMed  Google Scholar 

Song X, Cao L, Ni B, Wang J, Qin X, Sun X, Xu B, Wang X, Li J. Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: from mechanism to clinical practice. Front Pharmacol. 2023;14:1090500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhong J, Bai H, Wang Z, Duan J, Zhuang W, Wang D, Wan R, Xu J, Fei K, Ma Z, et al. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. Front Med. 2023;17(1):18–42.

Article  PubMed  Google Scholar 

Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499–514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortot AB, Madroszyk A, Giroux-Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, et al. First-line afatinib plus cetuximab for EGFR-mutant non-small cell lung cancer: results from the randomized phase II IFCT-1503 ACE-Lung Study. Clin Cancer Res. 2021;27(15):4168–76.

Article  CAS  PubMed  Google Scholar 

Zhang G, Yan B, Guo Y, Yang H, Li X, Li J. Case report: a patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy. Front Oncol. 2022;12:995624.

Article  PubMed  PubMed Central  Google Scholar 

Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos EDS, Nogueira KAB, Fernandes LCC, Martins JRP, Reis AVF, Neto JBV, Junior I, Pessoa C, Petrilli R, Eloy JO. EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm. 2021;592:120082.

Article  CAS  PubMed  Google Scholar 

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(1):e27048.

Article  PubMed  PubMed Central  Google Scholar 

Petrilli R, Eloy JO, Saggioro FP, Chesca DL, de Souza MC, Dias MVS, daSilva LLP, Lee RJ, Lopez RFV. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release. 2018;283:151–62.

Article  CAS  PubMed  Google Scholar 

Safaei M, Khosravian P, Kazemi Sheykhshabani S, Mardani G, Elahian F, Mirzaei SA. Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells. Toxicol Appl Pharmacol. 2022;441:115989.

Article  CAS  PubMed  Google Scholar 

Merino M, Zalba S, Garrido MJ. Immunoliposomes in clinical oncology: State of the art and future perspectives. J Control Release. 2018;275:162–76.

Article  CAS  PubMed  Google Scholar 

Singh A, Myklebust NN, Furevik SMV, Haugse R, Herfindal L. Immunoliposomes in acute myeloid leukaemia therapy: an overview of possible targets and obstacles. Curr Med Chem. 2019;26(28):5278–92.

Article  CAS  PubMed  Google Scholar 

Lu X, Liu S, Han M, Yang X, Sun K, Wang H, Mu H, Du Y, Wang A, Ni L, Zhang C. Afatinib-loaded immunoliposomes functionalized with cetuximab: a novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer. Int J Pharm. 2019;560:126–35.

Article  CAS  PubMed  Google Scholar 

Lu X, Liu S, Yang X, Han M, Sun K. Determination of tyrosine kinase inhibitor afatinib in rat plasma using LC-MS/MS and its application to in vivo pharmacokinetic studies of afatinib liposomes. J Pharm Biomed Anal. 2019;164:181–6.

Article  CAS  PubMed  Google Scholar 

Bou-Assaly W, Mukherji S. Cetuximab (erbitux). AJNR Am J Neuroradiol. 2010;31(4):626–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caroline B, Sundus Y, Dawn D, Carol G, Susan M. Cost analysis of cetuximab (Erbitux) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study. Br J Radiol. 2016;89(1068):20160105.

Article  PubMed  PubMed Central  Google Scholar 

Abu Lila AS, Ishida T. Liposomal Delivery Systems: Design optimization and current applications. Biol Pharm Bull. 2017;40(1):1–10.

Article  CAS  PubMed  Google Scholar 

van Elk M, Murphy BP, Eufrasio-da-Silva T, O’Reilly DP, Vermonden T, Hennink WE, Duffy GP, Ruiz-Hernandez E. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems. Int J Pharm. 2016;515(1–2):132–64.

Article  PubMed  Google Scholar 

Eloy JO, Petrilli R, Trevizan LNF, Chorilli M. Immunoliposomes: a review on functionalization strategies and targets for drug delivery. Colloids Surf B Biointerfaces. 2017;159:454–67.

Article  CAS  PubMed  Google Scholar 

Fei Q, Bentley I, Ghadiali SN, Englert JA. Pulmonary drug delivery for acute respiratory distress syndrome. Pulm Pharmacol Ther. 2023;79:102196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang RYK, Chow MYT, Khanal D, Chen D, Chan HK. Dry powder pharmaceutical biologics for inhalation therapy. Adv Drug Deliv Rev. 2021;172:64–79.

Article  CAS  PubMed  Google Scholar 

Marante T, Viegas C, Duarte I, Macedo AS, Fonte P. An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation. Pharmaceutics. 2020;12(11).

Carfagna M, Rosa M, Hawe A, Friess W. Lyophilization cycle design for highly concentrated protein formulations supported by micro freeze-dryer and heat flux sensor. Int J Pharm. 2023;643:123285.

Article  CAS  PubMed  Google Scholar 

Schmid B, Navalho S, Schulze PSC, Van De Walle S, Van Royen G, Schuler LM, Maia IB, Bastos CRV, Baune MC, Januschewski E, et al. Drying microalgae using an industrial solar dryer: A biomass quality assessment. Foods. 2022;11(13).

Jia W, Yawman PD, Pandya KM, Sluga K, Ng T, Kou D, Nagapudi K, Luner PE, Zhu A, Zhang S, Hou HH. Assessing the interrelationship of microstructure, properties, drug release performance, and preparation process for amorphous solid dispersions via noninvasive imaging analytics and material characterization. Pharm Res. 2022;39(12):3137–54.

Article  CAS  PubMed  Google Scholar 

Ramireddy BA, Gorantla A, Indukuri A, Beeravelly S, Sarbajna RM, Arikatla S, Jetti RR. Polymorphic Forms of Afatinib Dimaleate. 2018.

Kussendrager KD, Ellison MJ. Carrier material for dry powder inhalation. 2002.